Literature DB >> 32475824

Oral manifestations of Alagille syndrome.

Anne-Laure Bonnet1,2, Victor Greset3, Tiphaine Davit-Beal4,5.   

Abstract

Alagille syndrome (AGS) is a multisystem disorder classically involving liver and heart failure, characteristic vertebral and facial features and ocular abnormalities. AGS is caused by heterozygous mutations in JAG1 or NOTCH2, with variable phenotype penetrance. We report two cases of AGS in children with tooth defects characterised by green discolouration and hypomineralisation. The role of hyperbilirubinaemia (HB) in this atypical colour, a classical feature of AGS, has been well described. However, it does not totally explain the dental phenotype. As JAG1 and NOTCH2 mutations can affect bone development and considering common physiological pathways between bone and tooth mineralisation, both mutations could participate in this unusual dental phenotype. The role of HB and genetics in the development of the dental phenotype of AGS is discussed in two prototypical cases. Future research should focus on the underlying genetic component of tooth abnormalities. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  dentistry and oral medicine; metabolic disorders

Mesh:

Year:  2020        PMID: 32475824      PMCID: PMC7264826          DOI: 10.1136/bcr-2020-234689

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  35 in total

1.  Severe hypodontia and oral xanthomas in Alagille syndrome.

Authors:  N C Ho; F Lacbawan; C A Francomano; V Ho
Journal:  Am J Med Genet       Date:  2000-07-31

Review 2.  Alagille syndrome: pathogenesis, diagnosis and management.

Authors:  Peter D Turnpenny; Sian Ellard
Journal:  Eur J Hum Genet       Date:  2011-09-21       Impact factor: 4.246

3.  JAG1 mutations are found in approximately one third of patients presenting with only one or two clinical features of Alagille syndrome.

Authors:  K Guegan; K Stals; M Day; P Turnpenny; S Ellard
Journal:  Clin Genet       Date:  2011-07-31       Impact factor: 4.438

4.  NOTCH2 mutations in Alagille syndrome.

Authors:  Binita Maya Kamath; Robert C Bauer; Kathleen M Loomes; Grace Chao; Jennifer Gerfen; Anne Hutchinson; Winita Hardikar; Gideon Hirschfield; Paloma Jara; Ian D Krantz; Pablo Lapunzina; Laura Leonard; Simon Ling; Vicky Lee Ng; Phuc Le Hoang; David A Piccoli; Nancy Bettina Spinner
Journal:  J Med Genet       Date:  2011-12-29       Impact factor: 6.318

5.  Vertebral anomalies in children with Alagille syndrome: an analysis of 50 consecutive patients.

Authors:  Evelyn Sanderson; Vanessa Newman; Susan F Haigh; Alastair Baker; Paul S Sidhu
Journal:  Pediatr Radiol       Date:  2001-12-15

6.  Alagille syndrome: an overview.

Authors:  Pietro Vajro; Lorenza Ferrante; Giulia Paolella
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-04-18       Impact factor: 2.947

7.  Variable morbidity in alagille syndrome: a review of 43 cases.

Authors:  R E Quiros-Tejeira; M E Ament; M B Heyman; M G Martin; P Rosenthal; T R Hall; S V McDiarmid; J H Vargas
Journal:  J Pediatr Gastroenterol Nutr       Date:  1999-10       Impact factor: 2.839

8.  A report of 2 cases of green pigmentation in the primary dentition associated with cholestasis caused by sepsis.

Authors:  Antoniella Busuttil Naudi; Amera B Ammari; Diane E Fung
Journal:  J Dent Child (Chic)       Date:  2008 Jan-Apr

Review 9.  Renal involvement and the role of Notch signalling in Alagille syndrome.

Authors:  Binita M Kamath; Nancy B Spinner; Norman D Rosenblum
Journal:  Nat Rev Nephrol       Date:  2013-06-11       Impact factor: 28.314

10.  Anthropometric evaluation of children with chronic liver disease.

Authors:  R J Sokol; C Stall
Journal:  Am J Clin Nutr       Date:  1990-08       Impact factor: 7.045

View more
  1 in total

1.  Neurofibromatosis Type 1 With Cherubism-like Phenotype, Multiple Osteolytic Bone Lesions of Lower Extremities, and Alagille-syndrome: Case Report With Literature Survey.

Authors:  Reinhard E Friedrich; Jozef Zustin; Andreas M Luebke; Thorsten Rosenbaum; Martin Gosau; Christian Hagel; Felix K Kohlrusch; Ilse Wieland; Martin Zenker
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.